Cargando…

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide

BACKGROUND AND PURPOSE: Amino acid substitutions at the N‐termini of glucagon‐like peptide‐1 (GLP‐1) receptor agonist peptides result in distinct patterns of intracellular signalling, sub‐cellular trafficking and efficacy in vivo. Here, we to determine whether sequence differences at the ligand C‐te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pickford, Philip, Lucey, Maria, Fang, Zijian, Bitsi, Stavroula, de la Serna, Jorge Bernardino, Broichhagen, Johannes, Hodson, David J., Minnion, James, Rutter, Guy A., Bloom, Stephen R., Tomas, Alejandra, Jones, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429481/ https://www.ncbi.nlm.nih.gov/pubmed/32436216 http://dx.doi.org/10.1111/bph.15134

Ejemplares similares

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
por: Lucey, Maria, et al.
Publicado: (2021)

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
por: Marzook, Amaara, et al.
Publicado: (2021)

Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
por: Fang, Zijian, et al.
Publicado: (2020)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
por: Pickford, Phil, et al.
Publicado: (2021)

Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
por: Manchanda, Yusman, et al.
Publicado: (2023)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor
por: Jones, Ben J., et al.
Publicado: (2017)

Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors
por: Jones, Ben, et al.
Publicado: (2020)

The glucoregulatory actions of leptin
por: D'souza, Anna M., et al.
Publicado: (2017)

Indirect Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Peripheral Circadian Clocks in Mice
por: Ando, Hitoshi, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference
por: Zhu, Changliang, et al.
Publicado: (2021)

Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking
por: Fremaux, Juliette, et al.
Publicado: (2019)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
por: Cegla, Jaimini, et al.
Publicado: (2017)

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2021)

A glucagon analogue decreases body weight in mice via signalling in the liver
por: Hinds, Charlotte E., et al.
Publicado: (2021)

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles
por: Gautier, Thibault, et al.
Publicado: (2021)

Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
por: Scott, R., et al.
Publicado: (2018)

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia
por: Teramoto, Shinichiro, et al.
Publicado: (2011)

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret
por: Lu, Zengbing, et al.
Publicado: (2014)

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
por: Chen, Fangzhe, et al.
Publicado: (2016)

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice
por: Zhu, Changliang, et al.
Publicado: (2022)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
por: Arakawa, Masayuki, et al.
Publicado: (2010)

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
por: Seino, Y, et al.
Publicado: (2014)

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
por: Yanay, Ofer, et al.
Publicado: (2015)

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist
por: Sai, Wenbo, et al.
Publicado: (2017)

Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
por: Barrera, Jason G., et al.
Publicado: (2009)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
por: Yamamoto, Koji, et al.
Publicado: (2013)

SNAP-tag-enabled super-resolution imaging reveals constitutive and agonist-dependent trafficking of GPR56 in pancreatic β-cells
por: Olaniru, Oladapo E., et al.
Publicado: (2021)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

Periodontitis affects glucoregulatory hormones in severely obese individuals
por: Solini, Anna, et al.
Publicado: (2018)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()
por: Van Gaal, Luc, et al.
Publicado: (2014)

Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression
por: YI, BO, et al.
Publicado: (2014)

The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages
por: Shen, Wei-Ren, et al.
Publicado: (2018)

Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
por: Kim, Soojin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cn0uukjrmr4noeptuseesn50gi